Roflumilast

🧮 Dose calculator

Chronic obstructive pulmonary disease (COPD) · Regimen source: FDA Daliresp · 2

• • Optional: 250 mcg daily for 4 weeks to improve tolerability, then 500 mcg (250 is not a therapeutic dose). Not for acute bronchospasm. FDA Daliresp · 2FDA Daliresp · 5

Enter age (weight is optional for this regimen).

👥 Special populations

• 🤰 PregnancyUse with caution

  Label states no clear risk or has limited data; use only if needed, under medical advice. FDA Daliresp · 8.1

  “Risk Summary There are no randomized clinical studies of DALIRESP in pregnant women.”

• 🤱 BreastfeedingUse with caution

  Label: use with caution while breastfeeding; see the label text. FDA Daliresp · 8.2

  “Risk Summary There is no information regarding the presence of DALIRESP in human milk, the effects on the breastfed infant, or the effects on milk production.”

• 👶 ChildrenSafety not established

  Label: safety and effectiveness in children have not been established. FDA Daliresp · 8.4

  “The safety and effectiveness of DALIRESP in pediatric patients have not been established.”

• 👴 Older adultsUse with caution

  Label: use with caution in older adults, usually starting at the low end of the dose range. FDA Daliresp · 8.5

  “Of the 4438 COPD subjects exposed to DALIRESP for up to 12 months in 8 controlled clinical trials, 2022 were >65 years of age and 471 were >75 years of age.”

• ⚥ Females & males of reproductive potentialNo data

  The source for this drug has no section for this group.